申请人:E. R. Squibb & Sons, Inc.
公开号:US04602092A1
公开(公告)日:1986-07-22
A method is provided for preparing phosphinic acid prodrug intermediates which are useful in preparing phosphinic acid angiotensin-converting enzyme inhibitors which method includes the step of coupling a phosphonous acid or its ester of the structure ##STR1## wherein R is H or lower alkyl and R.sup.1 is lower alkyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl, with an alkylating agent of the structure ##STR2## wherein Hal is Cl, Br or I, n is 0 or 1, R.sup.2 is H or lower alkyl, and Z is H, lower alkyl, --CO.sub.2 R.sup.3 (wherein R.sup.3 is H or lower alkyl), ##STR3## (wherein R.sup.4 is H, lower alkyl, aryl or arylalkyl), --CN, or ##STR4## (wherein R.sup.5 and R.sup.6 may be the same or different and are selected from the group consisting of H, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkylalkyl and at least one of R.sup.5 and R.sup.6 is other than H, or R.sup.5 and R.sup.6 can be taken with the N-atom to form a 5-, 6- or 7-membered heterocyclic ring which 5-, 6- or 7-membered N-containing ring may or may not contain a CO.sub.2 R.sup.3 group and which 5- or 6-membered N-containing ring may or may not be fused to an aryl ring), in the presence of a silylating agent, to form the phosphinic acid intermediate of the structure ##STR5## wherein R, R.sup.1, R.sup.2, n and Z are as defined above.
提供了一种制备磷酸酰胺前药中间体的方法,该方法有助于制备磷酸酰胺型血管紧张素转化酶抑制剂,其中包括将具有以下结构的膦酸或其酯的磷酸酰胺偶联物与以下结构的烷基化剂偶联的步骤:##STR1## 其中R为H或较低的烷基,R.sup.1为较低的烷基、芳香族、芳香族烷基、环烷基或环烷基烷基,Hal为Cl、Br或I,n为0或1,R.sup.2为H或较低的烷基,Z为H、较低的烷基、--CO.sub.2 R.sup.3(其中R.sup.3为H或较低的烷基)、##STR3##(其中R.sup.4为H、较低的烷基、芳香族或芳香族烷基)、--CN或##STR4##(其中R.sup.5和R.sup.6可以相同也可以不同,且选自H、较低的烷基、芳香族、芳香族-较低的烷基、环烷基或环烷基烷基,且R.sup.5和R.sup.6中至少有一个不为H,或R.sup.5和R.sup.6可以与N原子结合形成5、6或7元杂环环,该5、6或7元杂环含有N原子,可以或不可以含有CO.sub.2 R.sup.3基团,该5或6元杂环可以或不可以与芳香族环融合)。在硅基化剂的存在下进行上述步骤,形成具有以下结构的磷酸酰胺中间体:##STR5## 其中R、R.sup.1、R.sup.2、n和Z如上所定义。